Jazz Pharmaceuticals plc (J7Z)

Overview

Jazz Pharmaceuticals plc is a leading biopharmaceutical company with a strong focus on identifying, developing, and commercializing innovative pharmaceutical products aimed at addressing unmet medical needs across the United States, Europe, and other international markets. Established in 2003 and based in Dublin, Ireland, the company has carved a niche in the pharmaceutical industry through its extensive product portfolio that caters to a variety of serious or life-threatening diseases, including narcolepsy, epilepsy, cancer, and acute lymphoblastic leukemia among others. Jazz Pharmaceuticals is committed to improving patient care through their significant investments in research and development (R&D), strategic licensing, and collaboration agreements to enhance their pipeline and deliver groundbreaking therapies to patients worldwide.

Products and Services

• Xywav - Approved for treating cataplexy or excessive daytime sleepiness (EDS) in narcolepsy patients and idiopathic hypersomnia. A prominent offering in their sleep disorder portfolio, Xywav represents Jazz Pharmaceuticals' dedication to providing relief to those suffering from debilitating sleep conditions.
• Xyrem - An earlier treatment for cataplexy or EDS associated with narcolepsy, Xyrem has been a cornerstone in managing this sleep disorder, showcasing the company's long-term commitment to narcolepsy patients.
• Epidiolex - A pioneering medication for treating seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. Epidiolex's approval marked a significant advancement in the care of patients with these rare and severe forms of epilepsy.
• Zepzelca - Targeted for the treatment of metastatic small cell lung cancer, particularly for those with disease progression after platinum-based chemotherapy. Zepzelca fills a critical gap in oncology, offering hope to patients with limited treatment options.
• Rylaze - Designed for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma. Rylaze provides an essential treatment option for patients with these aggressive blood cancers.
• Enrylaze - Another product focused on treating acute lymphoblastic leukemia and lymphoblastic lymphoma, demonstrating the company’s ongoing commitment to developing therapies for hematologic malignancies.
• Defitelio - The sole treatment for severe hepatic veno-occlusive disease, Defitelio is crucial for patients undergoing stem cell transplantation, underscoring Jazz Pharmaceuticals' role in addressing rare post-transplant complications.
• Vyxeos - A unique treatment for newly-diagnosed therapy-related acute myeloid leukemia, Vyxeos offers a novel approach for managing this complex and aggressive cancer.
• Developmental Therapies - Jazz Pharmaceuticals is also actively developing a range of promising therapies, including Zanidatamab for HER2-expressing gastroesophageal adenocarcinoma, Zepzelca for solid tumors, and several other compounds designed to treat Parkinson's disease, post-traumatic stress disorder, and sleep disorders.

Furthermore, Jazz Pharmaceuticals engages in essential collaborations, such as with XL-protein GmbH to extend the plasma half-life of asparaginase product candidates, Redx Pharma plc for a Ras/Raf/MAP kinase pathway program, and Autifony Therapeutics Limited for drug discovery focused on neurological disorders. These partnerships underscore their dedication to innovation and addressing complex medical challenges.